The trademark application was filed by Cytokinetics, Incorporated, a U.S. corporation (the "Applicant"). The application was published for oppositions on May 2, 2024, and it was registered by office on August 9, 2024 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with Pharmaceutical preparations for human use, namely, medications to treat cardiovascular conditions and pharmaceutical preparations to treat hypertrophic cardiomyopathies, heart failure, and heart failure with preserved ejection fraction..